… with Daiichi Pharmaceutical Corporation as an investigator. Dr. Garden has reported a
financial interest/relationship with Daiichi Pharmaceutical Corporation as an investigator. …

… , as well as the hitherto taken-for-granted ability to eat, speak, and breathe easily, as well as
… interventions for individual patients, and serve as a research tool to compare the symptom …

… superficially located HNCs as well as large neck volumes … dose sparing of nearby organs
such as the larynx, salivary glands, and … toxicity reductions (such as decreased feeding tube …

… /6 weeks including a 2-week rest after 38.4 Gy; or 4) accelerated fractionation with concomitant
boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field as a …

… For this report, a severe late toxicity was defined as any or all of the following events: grade
… tube data were collected, and this was used as the primary means of defining patients with …

… This investigation offers clues for additional study as to what indicators could signal the
need for plan adaptation during treatment. For example, because the rate of resolution of gross …

… all disease classified as 7th edition TNM stage III and most disease categorised as stage IVA
(… We defined lower neck lymph node involvement as level IV or Vb (ie, extension caudal to …

… The accuracy of this fiducial-based registration was not important for this study as long as
the same deformation could be approximated in clinical situations. However, the resulting …

… site unless pathology showed no disease, and death as a result of cancer or unknown
causes without a documented failure site) and DM as site of first failure. Other end points for this …

… The lower neck could be included in the IMRT fields by using proper contours of CTVs (1.8
Gy/fraction) and by keeping the dose to the larynx to as low as possible without compromising …